Literature DB >> 21039545

Pharmaceutical applications of cyclodextrins: basic science and product development.

Thorsteinn Loftsson1, Marcus E Brewster.   

Abstract

OBJECTIVES: Drug pipelines are becoming increasingly difficult to formulate. This is punctuated by both retrospective and prospective analyses that show that while 40% of currently marketed drugs are poorly soluble based on the definition of the biopharmaceutical classification system (BCS), about 90% of drugs in development can be characterized as poorly soluble. Although a number of techniques have been suggested for increasing oral bioavailability and for enabling parenteral formulations, cyclodextrins have emerged as a productive approach. This short review is intended to provide both some basic science information as well as data on the ability to develop drugs in cyclodextrin-containing formulations. KEY
FINDINGS: There are currently a number of marketed products that make use of these functional solubilizing excipients and new product introduction continues to demonstrate their high added value. The ability to predict whether cyclodextrins will be of benefit in creating a dosage form for a particular drug candidate requires a good working knowledge of the properties of cyclodextrins, their mechanism of solubilization and factors that contribute to, or detract from, the biopharmaceutical characteristics of the formed complexes.
SUMMARY: We provide basic science information as well as data on the development of drugs in cyclodextrin-containing formulations. Cyclodextrins have emerged as an important tool in the formulator's armamentarium to improve apparent solubility and dissolution rate for poorly water-soluble drug candidates. The continued interest and productivity of these materials bode well for future application and their currency as excipients in research, development and drug product marketing.
© 2010 The Authors. Journal compilation © 2010 Royal Pharmaceutical Society of Great Britain.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21039545     DOI: 10.1111/j.2042-7158.2010.01030.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  99 in total

1.  Intranasal administration of PACAP: uptake by brain and regional brain targeting with cyclodextrins.

Authors:  Naoko Nonaka; Susan A Farr; Tomoya Nakamachi; John E Morley; Masanori Nakamura; Seiji Shioda; William A Banks
Journal:  Peptides       Date:  2012-06-09       Impact factor: 3.750

2.  Sustained Small Molecule Delivery from Injectable Hyaluronic Acid Hydrogels through Host-Guest Mediated Retention.

Authors:  Joshua E Mealy; Christopher B Rodell; Jason A Burdick
Journal:  J Mater Chem B       Date:  2015-09-18       Impact factor: 6.331

3.  Bioresponsive peptide-polysaccharide nanogels - A versatile delivery system to augment the utility of bioactive cargo.

Authors:  Andrew W Simonson; Atip Lawanprasert; Tyler D P Goralski; Kenneth C Keiler; Scott H Medina
Journal:  Nanomedicine       Date:  2018-11-03       Impact factor: 5.307

4.  Physicomechanical, stability, and pharmacokinetic evaluation of aceclofenac dimethyl urea cocrystals.

Authors:  Hafsa Afzal; Nasir Abbas; Amjad Hussain; Sumera Latif; Kanwal Fatima; Muhammad Sohail Arshad; Nadeem Irfan Bukhari
Journal:  AAPS PharmSciTech       Date:  2021-02-09       Impact factor: 3.246

Review 5.  Cyclodextrin derivatives as anti-infectives.

Authors:  Vladimir A Karginov
Journal:  Curr Opin Pharmacol       Date:  2013-09-04       Impact factor: 5.547

6.  Inclusion complex of a new propiconazole derivative with β-cyclodextrin: NMR, ESI-MS and preliminary pharmacological studies.

Authors:  Narcisa Marangoci; Mihai Mares; Mihaela Silion; Adrian Fifere; Cristian Varganici; Alina Nicolescu; Calin Deleanu; Adina Coroaba; Mariana Pinteala; Bogdan C Simionescu
Journal:  Results Pharma Sci       Date:  2011-08-01

7.  Aerosolized drug-loaded nanoparticles targeting migration inhibitory factors inhibit Pseudomonas aeruginosa-induced inflammation and biofilm formation.

Authors:  Mohammad Doroudian; Andrew O'Neill; Ciaran O'Reilly; Aisling Tynan; Leona Mawhinney; Aoife McElroy; Shanice S Webster; Ronan MacLoughlin; Yuri Volkov; Michelle E Armstrong; George A O'Toole; Adriele Prina-Mello; Seamas C Donnelly
Journal:  Nanomedicine (Lond)       Date:  2020-11-26       Impact factor: 5.307

Review 8.  Cyclodextrin-based delivery systems for in vivo-tested anticancer therapies.

Authors:  Ana Cláudia Santos; Diana Costa; Laura Ferreira; Catarina Guerra; Miguel Pereira-Silva; Irina Pereira; Diana Peixoto; Nuno R Ferreira; Francisco Veiga
Journal:  Drug Deliv Transl Res       Date:  2021-02       Impact factor: 4.617

Review 9.  Continuous manufacturing of co-crystals: challenges and prospects.

Authors:  Rahul B Chavan; Rajesh Thipparaboina; Balvant Yadav; Nalini R Shastri
Journal:  Drug Deliv Transl Res       Date:  2018-12       Impact factor: 4.617

Review 10.  Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease.

Authors:  Elizabeth A Ottinger; Mark L Kao; Nuria Carrillo-Carrasco; Nicole Yanjanin; Roopa Kanakatti Shankar; Marjo Janssen; Marcus Brewster; Ilona Scott; Xin Xu; Jim Cradock; Pramod Terse; Seameen J Dehdashti; Juan Marugan; Wei Zheng; Lili Portilla; Alan Hubbs; William J Pavan; John Heiss; Charles H Vite; Steven U Walkley; Daniel S Ory; Steven A Silber; Forbes D Porter; Christopher P Austin; John C McKew
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.